摘要
结合加拿大、澳大利亚专利药谈判机制,分析不同协作模式下的关键路径,进而根据我国谈判机制改革现状,提出有针对性的政策建议。虽然加澳的谈判模式是2种截然不同的选择,但两国都引入了卫生技术评估手段、取向多元的博弈方式和严格保密的价格协议。建议我国在谈判机制法制化的基础上,引入基于证据的评估工具,并加强标准化评估体系的构建。
To introduce the experience of patent drug negotiation in Canada and Australia,analyze key routes in different collaboration modes,and propose policy recommendations for the reform of China’s negotiation mechanism.Although Canada and Australia chose two distinct modes,both countries introduced health technology assessment,diversified value orientation,and confidential price agreement.It is suggested that on the legalization of the negotiation mechanism,evidence-based assessment tools be introduced,and a standardized assessment system be established.
作者
陶田甜
黄秋雨
侯立丽
张迪
邵蓉
TAO Tian-tian;HUANG Qiu-yu;HOU Li-li;ZHANG Di;SHAO Rong(School of International Pharmaceutical Business,China Pharmaceutical University,Nanjing 211198,Jiangsu China)
出处
《中国卫生资源》
北大核心
2019年第5期391-396,共6页
Chinese Health Resources
关键词
药品谈判
谈判机制
专利药
医疗保险
药品准入
药品统一审评
卫生技术评估
保密协议
加拿大
澳大利亚
drug negotiation
negotiation mechanism
patent drug
medical insurance
drug access
common drug review
health technology assessment
confidentiality agreement
Canada
Australia